Tradewinds LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

Tradewinds LLC’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,707	Closed	-$201K	–	132
2022 Q4	$201K	Buy	+2,707	New	+$254K	0.13%	117

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Tradewinds LLC's BMRN Position: Q1 2023 in Review

Tradewinds LLC sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 2,707 shares — an estimated $201K sold.

Tradewinds LLC first reported a position in BMRN in Q4 2022 and held it in 1 quarter. The position peaked at $201K in Q4 2022. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

Tradewinds LLC reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Tradewinds LLC sold 2,707 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $201K.
Tradewinds LLC first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Tradewinds LLC's BioMarin Pharmaceuticals position peaked at $201K in Q4 2022.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Tradewinds LLC's 13F filing for Q1 2023, filed 6 Apr 2023.